Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re

Journal of Nuclear Medicine

Volumn 45, Issue 2, 2004, Pages 327-337

  Brouwers, Adrienne H ^a   Van Eerd, Julliëtte E M ^a   Frielink, Cathelijne ^a   Oosterwijk, Egbert ^a   Oyen, Wim J G ^a   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chelates; Experimental radioimmunotherapy; Monoclonal antibody cG250; Radionuclides; Renal cell carcinoma

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; IODINE 131; ISOTHIOCYANATOBENZYLPENTETIC ACID; LUTETIUM 177; MERTIATIDE; MONOCLONAL ANTIBODY G250; MONOCLONAL ANTIBODY G250 I 125; MONOCLONAL ANTIBODY G250 I 131; MONOCLONAL ANTIBODY G250 LU 177; MONOCLONAL ANTIBODY G250 RE 186; MONOCLONAL ANTIBODY G250 Y 90; PENTETIC ACID; PENTETIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; TRIGLYCINE; UNCLASSIFIED DRUG; YTTRIUM 90; 1 (4 ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID; 1-(4-ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINEPENTAACETIC ACID; DRUG DERIVATIVE; LUTETIUM; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; RADIOISOTOPE; RHENIUM; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; ISOTOPE LABELING; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR VOLUME; ANIMAL; HUMAN; KIDNEY TUMOR; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; HUMANS; IODINE RADIOISOTOPES; ISOTOPE LABELING; KIDNEY NEOPLASMS; LUTETIUM; MICE; MICE, NUDE; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RHENIUM; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 1542399581     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol. 1997;15:1529-1537.
2. 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res. 1999;5(suppl):3268S-3274S.
3. De Jong M, Breeman WA, Bernard BF, et al. Tumor response after [(90)Y-DOTA(0), TYR(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001;42:1841-1846.
4. Muller WA, Schaffer EH, Linzner U. Studies on incorporated short-lived beta-emitters with regard to the induction of late effects. Radiat Environ Biophys. 1980;18:1-11.
5. 90Y labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 1988;48:3270-3275.
6. Hnatowich DJ, Childs RL, Lanteigne D, et al. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: an improved method. J Immunol Methods. 1983;65:147-157.
7. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistributions of yttriumand indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med. 1989;30:672-682.
8. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res. 1989;49:2639-2644.
9. 90Y from cyclic and acyclic ligand-antibody conjugates. Int J Rad Appl Instrum B. 1991;18:469-476.
10. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol. 2002;29:431-442.
11. Griffiths GL, Goldenberg DM, Knapp FF Jr, et al. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies. Cancer Res. 1991;51:4594-4602.
12. Visser GW, Gerretsen M, Herscheid JD, et al. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J Nucl Med. 1993;34:1953-1963.
13. Fritzberg AR, Abrams PG, Beaumier PL, et al. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Natl Acad Sci USA. 1988;85:4025-4029.
14. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489-494.
15. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res. 1994;54:1753-1759.
16. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85:865-870.
17. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741-746.
18. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology. 1997;112:398-408.
19. Ruegg CL, Anderson-Berg WT, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 1990;50:4221-4226.
20. Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug Chem. 1994;5:565-576.
21. 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm. 1998;13:133-139.
22. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
23. Ebert T, Bander NH, Finstad CL, et al. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 1990;50:5531-5536.
24. Stabin MG. MIRDOSE personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
25. Schrijvers AH, Quak JJ, Uyterlinde AM, et al. MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:4383-4390.
26. Camera L, Kinuya S, Garmestani K, et al. Evaluation of the serum stability and in vivo biodistribution of CHX- DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med. 1994;35:882-889.
27. 90Yttrium-labeled complementarity-determining region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies. Bioconjug Chem. 1998;9:773-782.
28. 131I. J Nucl Med. 2001;42:967-974.
29. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
30. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
31. Geissler F, Anderson SK, Venkatesan P, et al. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res. 1992;52:2907-2915.
32. Sharkey RM, Behr TM, Mattes MJ, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997;44:179-188.
33. 90Y labeled mAbs. Cancer Biother Radiopharm. 1999;14:37-47.
34. Stein R, Chen S, Haim S, et al. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft. Cancer. 1997;80(suppl):2636-2641.
35. Stein R, Goldenberg DM, Thorpe SR, et al. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res. 1995;55:3132-3139.
36. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res. 2003;63:111-118.
37. Kievit E, van Gog FB, Schlüper HMM, et al. Comparison of the biodistribution and efficacy of monoclonal antibody 323/A3 labeled with either 131-I or 186-Re in human ovarian cancer xenografts. Int J Radiat Oncol Biol Phys. 1997;38:813-823.
38. De Jong M, Breeman WA, Bernard HF, et al. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: tumour size versus curability [abstract]. Eur J Nucl Med. 2001;28:1026.
39. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35:152-156.
40. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902-1909.
41. 111In: an intrapatient comparison. Clin Cancer Res. 2003;9(suppl):3953S-3960S.